文献速递脑血管病外科

导航引导下脑出血导管溶栓冲洗中tPA与尿激酶再出血风险比较

Comparison of rebleeding risk after navigation-guided catheterization and thrombolytic irrigation using tPA or urokinase in intracerebral hemorrhage.
PubMed 文献 · Acta Neurochir (Wien) · 2026-07-30

本研究回顾性分析2018年1月至2023年12月接受导航引导下导管置入并腔内溶栓的自发性幕上脑出血成人患者,比较尿激酶与tPA的再出血风险及早期结局。结果显示tPA组再出血率显著高于尿激酶组(26.7% vs 5.7%,p=0.032),校正后tPA仍与再出血独立相关(aOR 5.03,95%CI 1.12-22.64,p=0.035),两组第4天平均血肿体积缩小相似,但尿激酶组早期mRS和GCS变化更有利。

要点

  • tPA组再出血率26.7%,显著高于尿激酶组5.7%(p=0.032)。
  • 校正混杂因素后tPA仍与再出血独立相关(aOR 5.03,95%CI 1.12-22.64)。
  • 两组第4天平均血肿缩小相似,尿激酶组早期神经功能变化更有利。

核心结论

  • 在导航引导下导管微创治疗自发性幕上脑出血中,尿激酶较tPA与更低的再出血风险和更有利的早期神经结局相关,尽管两组平均血肿缩小程度相当。

主要发现

  • tPA组再出血12/45例(26.7%),尿激酶组2/35例(5.7%),差异有统计学意义(p=0.032)。
  • 并发脑室内出血是再出血的强危险因素。
  • 校正并发脑室内出血、症状至手术时间和基线血肿体积后,tPA使用仍与再出血相关(校正比值比5.03;95%置信区间1.12-22.64;p=0.035)。
  • 两组第4天平均血肿体积缩小相似,但tPA组体积变化变异更大。
  • 早期mRS和GCS变化有利于尿激酶组。

关键数值与推荐

  • 再出血定义为影像学上血肿扩大或复发并伴神经功能恶化。
  • 主要结局为再出血,次要结局包括基线至第4天血肿体积变化及mRS和GCS短期变化。

临床怎么用

  • 在导航引导下导管溶栓冲洗治疗自发性幕上脑出血时,选择尿激酶可能较tPA降低再出血风险并改善早期神经功能。
  • 对合并脑室内出血的患者,使用tPA时需更警惕再出血风险。

局限性

  • tPA组初始收缩压更高且基线血肿体积趋于更大,虽经统计校正仍可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive catheter-based evacuation is increasingly used for spontaneous intracerebral hemorrhage (ICH). Urokinase and tissue plasminogen activator (tPA) are used for intracatheter thrombolytic irrigation; however, direct comparative data on their safety, particularly regarding rebleeding risk, remain limited. This study aimed to compare rebleeding risk and early outcomes between urokinase and tPA after navigation-guided catheterization. METHODS: We retrospectively analyzed adults with spontaneous supratentorial ICH who underwent stereotactic, navigation-guided catheter placement followed by scheduled intracavitary thrombolysis between January 2018 and December 2023. Patients received either urokinase or tPA. The primary outcome was rebleeding, defined as hematoma expansion or recurrence on imaging with neurological deterioration. Secondary outcomes were hematoma volume change from baseline to day 4 and short-term changes in modified Rankin Scale (mRS) and Glasgow Coma Scale (GCS). Penalized logistic regression, multivariable linear regression, and ordinal logistic regression models were used to adjust for baseline imbalances and evaluate radiologic and short-term functional outcomes. RESULTS: Eighty patients were included (urokinase, n = 35; tPA, n = 45). tPA-treated patients presented with higher initial systolic blood pressure and tended to have larger baseline hematoma volumes. Rebleeding occurred in 12/45 patients (26.7%) in the tPA group versus 2/35 (5.7%) in the urokinase group (p = 0.032), and the presence of concurrent intraventricular hemorrhage (IVH) was a potent risk factor. After adjustment for concurrent IVH, symptom onset-to-surgery time, and baseline hematoma volume using a penalized multivariable model, tPA use remained associated with rebleeding (adjusted odds ratio,5.03; 95% confidence interval,1.12-22.64; p = 0.035). Mean hematoma volume reduction by day 4 was similar between groups, although volume change was more variable in the tPA group. Early shifts in mRS and GCS favored urokinase. CONCLUSIONS: In catheter-based minimally invasive treatment of spontaneous supratentorial ICH, urokinase was associated with a lower risk of rebleeding and more favorable early neurological outcomes than tPA, despite comparable mean hematoma reduction.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Song, Cho, Koo, et al. Comparison of rebleeding risk after navigation-guided catheterization and thrombolytic irrigation using tPA or urokinase in intracerebral hemorrhage. Acta Neurochir (Wien). 2026. PMID: 42946870. doi:10.1007/s00701-026-06995-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。